Jim Birchenough
Stock Analyst at Wells Fargo
(2.83)
# 1,639
Out of 5,132 analysts
30
Total ratings
52.63%
Success rate
37.79%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jim Birchenough
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SGMO Sangamo Therapeutics | Maintains: Equal-Weight | $3 → $2 | $0.38 | +427.98% | 2 | Dec 31, 2024 | |
| CRSP CRISPR Therapeutics AG | Maintains: Equal-Weight | $55 → $70 | $48.93 | +43.06% | 3 | Feb 22, 2024 | |
| ZYME Zymeworks | Maintains: Overweight | $56 → $48 | $23.17 | +107.16% | 3 | Feb 9, 2022 | |
| FATE Fate Therapeutics | Maintains: Overweight | $84 → $130 | $1.20 | +10,733.33% | 4 | Mar 4, 2021 | |
| PGEN Precigen | Initiates: Overweight | $14 | $4.74 | +195.36% | 1 | Feb 22, 2021 | |
| MRNA Moderna | Maintains: Equal-Weight | $129 → $145 | $40.11 | +261.51% | 2 | Feb 1, 2021 | |
| GILD Gilead Sciences | Maintains: Equal-Weight | $69 → $63 | $151.81 | -58.50% | 5 | Oct 29, 2020 | |
| RNA Avidity Biosciences | Initiates: Overweight | n/a | $72.91 | - | 1 | Jul 7, 2020 | |
| QURE uniQure | Downgrades: Equal-Weight | $56 | $22.37 | +150.34% | 3 | Jun 25, 2020 | |
| REGN Regeneron Pharmaceuticals | Upgrades: Overweight | $734 | $783.65 | -6.34% | 2 | May 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $300 → $180 | $6.31 | +2,752.61% | 1 | Mar 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $33 | $10.69 | +208.70% | 3 | Jun 28, 2018 |
Sangamo Therapeutics
Dec 31, 2024
Maintains: Equal-Weight
Price Target: $3 → $2
Current: $0.38
Upside: +427.98%
CRISPR Therapeutics AG
Feb 22, 2024
Maintains: Equal-Weight
Price Target: $55 → $70
Current: $48.93
Upside: +43.06%
Zymeworks
Feb 9, 2022
Maintains: Overweight
Price Target: $56 → $48
Current: $23.17
Upside: +107.16%
Fate Therapeutics
Mar 4, 2021
Maintains: Overweight
Price Target: $84 → $130
Current: $1.20
Upside: +10,733.33%
Precigen
Feb 22, 2021
Initiates: Overweight
Price Target: $14
Current: $4.74
Upside: +195.36%
Moderna
Feb 1, 2021
Maintains: Equal-Weight
Price Target: $129 → $145
Current: $40.11
Upside: +261.51%
Gilead Sciences
Oct 29, 2020
Maintains: Equal-Weight
Price Target: $69 → $63
Current: $151.81
Upside: -58.50%
Avidity Biosciences
Jul 7, 2020
Initiates: Overweight
Price Target: n/a
Current: $72.91
Upside: -
uniQure
Jun 25, 2020
Downgrades: Equal-Weight
Price Target: $56
Current: $22.37
Upside: +150.34%
Regeneron Pharmaceuticals
May 26, 2020
Upgrades: Overweight
Price Target: $734
Current: $783.65
Upside: -6.34%
Mar 13, 2020
Maintains: Overweight
Price Target: $300 → $180
Current: $6.31
Upside: +2,752.61%
Jun 28, 2018
Maintains: Outperform
Price Target: $31 → $33
Current: $10.69
Upside: +208.70%